NASDAQ:VRAY - Viewray Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $9.23 +0.09 (+0.98 %) (As of 07/19/2018 05:27 AM ET)Previous Close$9.14Today's Range$9.10 - $9.5452-Week Range$4.40 - $10.64Volume1.19 million shsAverage Volume691,810 shsMarket Capitalization$643.54 millionP/E Ratio-8.88Dividend YieldN/ABeta0.57 Company ProfileAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed. Receive VRAY News and Ratings via Email Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical SymbolNASDAQ:VRAY CUSIPN/A Webwww.viewray.com Phone440-703-3210 Debt Debt-to-Equity Ratio0.77 Current Ratio3.79 Quick Ratio3.04 Price-To-Earnings Trailing P/E Ratio-8.88 Forward P/E Ratio-13.98 P/E GrowthN/A Sales & Book Value Annual Sales$34.04 million Price / Sales19.45 Cash FlowN/A Price / CashN/A Book Value$0.03 per share Price / Book307.67 Profitability EPS (Most Recent Fiscal Year)($1.04) Net Income$-72,170,000.00 Net Margins-83.09% Return on Equity-1,375.57% Return on Assets-44.36% Miscellaneous Employees139 Outstanding Shares71,740,000Market Cap$643.54 Viewray (NASDAQ:VRAY) Frequently Asked Questions What is Viewray's stock symbol? Viewray trades on the NASDAQ under the ticker symbol "VRAY." How were Viewray's earnings last quarter? Viewray Inc (NASDAQ:VRAY) posted its quarterly earnings results on Thursday, May, 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.09. The company had revenue of $26.19 million for the quarter, compared to the consensus estimate of $15.50 million. Viewray had a negative net margin of 83.09% and a negative return on equity of 1,375.57%. The company's revenue for the quarter was up 2029.3% on a year-over-year basis. During the same period last year, the firm posted ($0.54) EPS. View Viewray's Earnings History. What price target have analysts set for VRAY? 6 brokers have issued 12 month target prices for Viewray's stock. Their predictions range from $10.00 to $13.50. On average, they anticipate Viewray's share price to reach $11.9167 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Ratings for Viewray. What is the consensus analysts' recommendation for Viewray? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Viewray stock? Here are some recent quotes from research analysts about Viewray stock: 1. Cantor Fitzgerald analysts commented, "Strong 1Q results. VRAY reported $26.2MM of revenue in 1Q, beating Street expectations by $13.1MM. Revenue was higher than expected due to delayed revenue recognition of a system installed in 4Q, earlier-than-expected recognition from an installation in late-1Q, and a system upgrade from the previous generation MRIdian Cobalt. VRAY placed four systems and upgraded one, which was in line with our expectations. VRAY received gross orders of $21MM, slightly below our expectation of $24MM. The backlog at the end of the quarter was $195MM, down slightly from $204MM last quarter." (5/11/2018) 2. Mizuho analysts commented, "We were at the Advanced Applications of MR-Guided Radiotherapy Symposium in Amsterdam on March 16th, 2018. The event was very well attended with approximately 200 people; most were potential customers who showed strong interest in ViewRay’s MRIdian. We highlight our key takeaways from the conference and additional insights into the MRI Linac below. Overall, we maintain our view that ViewRay has leadership in real time imaging guided LINAC today." (4/19/2018) Who are some of Viewray's key competitors? Some companies that are related to Viewray include GETINGE AB/ADR (GNGBY), CONMED (CNMD), AxoGen, Inc Common Stock (AXGN), NxStage Medical (NXTM), Natus Medical (BABY), Cutera (CUTR), BioLife Solutions (BLFS), Vision Sciences (CGNT), Rockwell Medical (RMTI), Fonar (FONR), Helius Medical Technologies (HSDT), Second Sight Medical Products (EYES), Edap Tms (EDAP), Zynex Inc. common stock (ZYXI) and Semler Scientific (SMLR). When did Viewray IPO? (VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers. Has Viewray been receiving favorable news coverage? Press coverage about VRAY stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viewray earned a daily sentiment score of 0.13 on Accern's scale. They also gave news articles about the company an impact score of 46.34 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. Who are Viewray's major shareholders? Viewray's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.43%). Company insiders that own Viewray stock include Aditya Puri, Ajay Bansal, David P Bonita, Fmr Llc, Henry A Mckinnell and James F Dempsey. View Institutional Ownership Trends for Viewray. Which institutional investors are buying Viewray stock? VRAY stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Company insiders that have bought Viewray stock in the last two years include Aditya Puri, Ajay Bansal, David P Bonita and Henry A Mckinnell. View Insider Buying and Selling for Viewray. How do I buy shares of Viewray? Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Viewray's stock price today? One share of VRAY stock can currently be purchased for approximately $9.23. How big of a company is Viewray? Viewray has a market capitalization of $643.54 million and generates $34.04 million in revenue each year. The company earns $-72,170,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Viewray employs 139 workers across the globe. How can I contact Viewray? Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected] MarketBeat Community Rating for Viewray (NASDAQ VRAY)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 136 (Vote Outperform)Underperform Votes: 87 (Vote Underperform)Total Votes: 223MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?